Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UroMed

This article was originally published in The Gray Sheet

Executive Summary

Voluntary bankruptcy filing under Chapter 7 in Boston federal court, announced May 15, "will result in the complete liquidation of the company's assets," UroMed says. The firm, doing business under the name Alliant Medical Technologies, offers brachytherapy seeds and needles for prostate cancer, treatment planning software for brachytherapy and external beam radiation therapy, and the CaverMap surgical aid for prostate and colorectal cancer surgery. Revenues in 2001 reached $6.1 mil., up 41.6%. However, the firm was unable to commercialize its products successfully, generating an accumulated deficit of $117.2 mil. as of December 2001...

You may also be interested in...



Blue Torch Aims Low: Negative Medicare NCD Could Boost Business, It Says

Blue Torch Medical paradoxically expects that a Medicare national non-coverage decision for its CaverMap diagnostic to assess a patient's risk of impotency after radical prostatectomy will lead to increased sales

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

Hair Supplement Linked To Cases Of Severe Hepatitis In France

France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.

UsernamePublicRestriction

Register

OM014142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel